OncoMatch/Clinical Trials/NCT06910657
IDOV-Immune for Advanced Solid Tumors
Is NCT06910657 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies IDOV-Immune (oncolytic vaccinia virus) for colorectal cancer.
Treatment: IDOV-Immune (oncolytic vaccinia virus) — This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not responded to standard treatments. Oncolytic viruses are designed to infect and destroy cancer cells and have the potential to stimulate the immune system to fight the tumor. The purpose of this study is to determine the safety of IDOV-Immune, how well it is tolerated, and to identify the highest dose that can be safely given. Researchers will also study how the drug behaves in the body, how the immune system responds to it, and whether it shows any signs of shrinking tumors. Participants will receive a single intravenous (IV) infusion of IDOV-Immune and will be closely monitored for side effects and any changes in their cancer. This study is being conducted at multiple sites in the United States and Australia.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Pancreatic Cancer
Melanoma
Ovarian Cancer
Gastric Cancer
Esophageal Carcinoma
Hepatocellular Carcinoma
Renal Cell Carcinoma
Breast Carcinoma
Sarcoma
Urothelial Carcinoma
Non-Small Cell Lung Carcinoma
Prostate Cancer
Cervical Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: oncolytic virus
Lab requirements
Blood counts
adequate organ and bone marrow function
Kidney function
adequate organ and bone marrow function
Liver function
adequate organ and bone marrow function
Adequate organ and bone marrow function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Washington University School of Medicine · St Louis, Missouri
- MD Anderson Cancer Center · Houston, Texas
- South Texas Accelerated Research Therapeutics · San Antonio, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify